Category Press Releases

AskBio Publishes Full Phase 1b Results of AB-1005 Gene Therapy for Parkinson’s Disease

AskBio Publishes Complete Phase 1b Trial Results of AB-1005 Gene Therapy for Parkinson’s Disease in Leading Neurology Journal Asklepios BioPharmaceutical, Inc. (AskBio), a pioneering gene therapy company that operates as a wholly owned, independent subsidiary of the global pharmaceutical giant…

Read MoreAskBio Publishes Full Phase 1b Results of AB-1005 Gene Therapy for Parkinson’s Disease

Cullinan, Taiho to Present Positive Zipalertinib Phase 2b Results at ASCO 2025

Cullinan Therapeutics and Taiho Highlight Promising Phase 2b Results of Zipalertinib in Advanced EGFR ex20ins NSCLC at ASCO 2025 Cullinan Therapeutics,in collaboration with Taiho Pharmaceutical Co., Ltd., and its U.S. affiliate Taiho Oncology, Inc., has announced encouraging new results from…

Read MoreCullinan, Taiho to Present Positive Zipalertinib Phase 2b Results at ASCO 2025

Lilly’s Kisunla Approved in Australia for Early Alzheimer’s Treatment

Lilly’s Kisunla (Donanemab) Gains Marketing Authorization in Australia for Early Alzheimer’s Treatment Eli Lilly and Company has announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), a novel treatment for early symptomatic Alzheimer’s disease.…

Read MoreLilly’s Kisunla Approved in Australia for Early Alzheimer’s Treatment